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BSTRACT
nder the auspices of the American College of Cardiology
oundation (ACCF) together with key specialty and subspe-
ialty societies, appropriateness reviews were conducted for 2
elatively new clinical cardiac imaging modalities, cardiac
omputed tomography (CCT) and cardiac magnetic resonance
CMR) imaging. The reviews assessed the risks and benefits of
he imaging tests for several indications or clinical scenarios
nd scored them based on a scale of 1 to 9, where the upper
ange (7 to 9) implies that the test is generally acceptable and
s a reasonable approach, and the lower range (1 to 3) implies
hat the test is generally not acceptable and is not a reasonable
pproach. The mid-range (4 to 6) indicates an uncertain
linical scenario. The indications for these reviews were drawn
rom common applications or anticipated uses, as few clinical
ractice guidelines currently exist for these techniques. These
ndications were reviewed by an independent group of clini-
ians and modified by the Working Group, and then panelists
ated the indications based on the ACCF Methodology for
valuating the Appropriateness of Cardiovascular Imaging,
hich blends scientific evidence and practice experience. A
odified Delphi technique was used to obtain first and second
ound ratings of clinical indications after the panelists were
rovided with a set of literature reviews, evidence tables, and
eminal references. The final ratings were evenly distributed
mong the 3 categories of appropriateness for both CCT and
MR. Use of tests for structure and function and for diagnosis
n symptomatic, intermediate coronary artery disease (CAD)
isk patients was deemed appropriate, while repeat testing and
eneral screening uses were viewed less favorably. It is antici-
ated that these results will have a significant impact on
hysician decision making and performance, reimbursement
olicy, and future research directions.
REFACE
he following paper combines the second and third reports
n an ongoing series of technical documents that critically
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October 3, 2006:1475–97 Appropriateness Criteria for CCT/CMRnd systematically create, review, and categorize appropri-
teness criteria for cardiovascular diagnostic tests and pro-
edures utilized by physicians caring for patients with
ardiovascular diseases. The ACCF believes that a careful
lending of a broad range of clinical experience and available
vidence-based information can help guide a more efficient
nd equitable allocation of health care resources in imaging.
he ultimate objective of these reviews is to improve patient
are and health outcomes in a cost-effective manner based
n current understanding of the limits of the imaging
odalities examined, without constraining the crucial role
f physician judgment in the face of diverse clinical presen-
ations and varying patient characteristics. Although there
re a limited number of studies available to evaluate the
echniques examined in these reports, the appropriateness
riteria hopefully can serve as initial guides for the respon-
ible use of CCT and CMR and related resources. Our
pproach is not to diminish the acknowledged ambiguity of
linical decision making for certain patients by statistical
eans or consensus techniques, but to recognize that real
ifferences in clinical opinion can exist for particular patient
resentation, especially in an evolving field with limited
vidence. Such differences are grounds for more research
nd for even more careful deliberation on the proper care for
ach indication and patient. These reports will need to be
pdated more frequently than most policy statements as
urther data and information are gained about their use. Not
rdering a test when it would be otherwise considered
ppropriate may be the correct clinical decision, and is a
udgment call based on the individual characteristics of
atients and their particular clinical scenarios. Likewise,
rdering a test for an indication deemed inappropriate may
e the correct clinical pathway if supported by mitigating
haracteristics of the patient that could justify this approach.
This work was not possible without the dedicated work of
he Technical Panel, composed of clinician experts, some
ith special background in cardiac imaging and others with
mpeccable credentials in general cardiovascular medicine,
ealth services research, and health plan administration.
his diversity in backgrounds of the Technical Panel as
hown in Appendix C made for a wide range of scoring for
any of the indications. It is much easier to “game” or “bias”
he scoring process by limiting panel membership solely to
pecialists of the particular procedure being evaluated for
ppropriateness. Such specialists would have a natural ten-
ency to rate each indication higher than non-specialists in
given test or procedure. Thus, it is with gratitude that we
pplaud the Technical Panel, a professional group with a
ide range of skills and insights, for a considered and
horough deliberation of the merits of each test for every
ndication.
Special mention and thanks are due to Elliott Antman,
D, FACC; Ronald Peshock, MD, FACC; Gregory
homas, MD, FACC; and Samuel Wann, MD, FACC, for
eviewing the draft indications; to Joe Allen, who continu-
lly drove the process forward; and to ACCF Past President damela Douglas, MD, MACC, for her insight and leader-
hip.
Robert Hendel, MD, FACC
Moderator, CCT/CMR Technical Panel
Ralph Brindis, MD, MPH, FACC
Chair, Appropriateness Criteria Working Group
NTRODUCTION
apid technological advances and new clinical applications in
ardiovascular imaging technology, coupled with increasing
herapeutic options for cardiovascular disease, have led to
xplosive growth in cardiovascular imaging. In fact, diagnostic
maging services reimbursed under Medicare’s physician fee
chedule grew more rapidly than any other type of physician
ervice from 1999 to 2003 (1). During this time, the arma-
entarium of non-invasive diagnostic tools has expanded with
nnovations in contrast agents; molecular radionuclide imag-
ng; perfusion echocardiography; CT for coronary angiogra-
hy, cardiac structure and morphology, and calcium scoring
nd CMR for myocardial structure, function, and viability.
hese advances present new opportunities for physicians to
tilize non-invasive techniques to gain important information
bout the condition of their patients. However, in the case of
CT and CMR, both tests are relatively expensive technolo-
ies, especially with regards to imaging equipment. Addition-
lly, the potential for uncontrolled utilization and stimulation
f downstream testing and treatment such as unwarranted
oronary revascularization has raised substantial concern from
overnment and private payers as well as clinical thought
eaders of evidenced-based cardiovascular medicine. As each of
hese imaging modalities becomes clinically available, the
ealth care community needs to understand how to incorpo-
ate these advances into acceptable clinical care.
Both CCT and CMR have been recognized as having a
umber of potential uses and advantages over existing technol-
gy. Coronary calcium scoring performed with either electron
eam CT or multidetector row CT is one application that has
ained some acceptance, despite the lack of reimbursement
rom most payers. Still, there has been, to date, little expert
onsensus regarding for whom this method is of clinical
enefit. Computed tomographic angiography, while very
romising with regard to the detection of coronary stenoses,
efinition of “soft plaque,” assessment of left ventricular func-
ion and congenital coronary anomalies, and evaluation of
ardiac structures, has limited data supporting its use for many
linical applications, especially with regard to its role within
atient care algorithms. Cardiac magnetic resonance imaging,
lthough continuing to demonstrate clinical utility, has been
sed primarily in specialized centers and, until recently, has had
ts major role in clinical research evaluating myocardial viability
nd cardiac structure and function. Cardiac magnetic reso-
ance also has been found useful in the evaluation of ischemic
eart disease with vasodilator stress perfusion imaging and
obutamine stress function imaging.
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Appropriateness Criteria for CCT/CMR October 3, 2006:1475–97In an effort to respond to the need for the rational use of
hese newer imaging techniques, CCT and CMR, the ACCF,
n conjunction with the societies listed on this report, under-
ook a process to determine the appropriateness of selected
ndications for these rapidly evolving cardiovascular imaging
rocedures. The Appropriateness Criteria Project was initiated
o support the delivery of quality cardiovascular care and to
nsure the effective use of diagnostic imaging tools, and it is an
ngoing effort by ACCF to rigorously examine the appropri-
teness of all established imaging modalities.
ETHODS
detailed description of the methods used for ranking of the
linical indications is outlined in Appendices A and B and also
ore generally can be found in a previous publication entitled,
ACCF Proposed Method for Evaluating the Appropriateness
f Cardiovascular Imaging” (2). Briefly, this process blends
cientific evidence and practice experience by engaging a
echnical Panel in a modified Delphi exercise. The Technical
anel was purposely balanced with a diverse set of individuals
ho ranged from imaging specialists within the CCT and
MR community including cardiologists and radiologists to
eferring physicians, health services researchers, and a medical
irector from a private payer. The panel members are high-
ighted in Appendix C.
The 39 CCT and 33 CMR indications that were rated are
hought to encompass the majority of cases referred for CCT
nd CMR, respectively. They were constructed by several
xperts within the field and were modified slightly based on
iscussions of the Working Group, indication reviewers, and
he panelists who rated the indications. Although not compre-
ensive, they are characteristic of contemporary practice. They
nclude symptomatic patients stratified by pre-test probability
f disease, asymptomatic patients based on Framingham risk,
nd patient presentation for assessment of structure and func-
ion, including coronary artery anomalies (3–7).
A reference list of key publications within the fields of CCT
nd CMR was provided to the raters. Additionally, evidence
ables for various applications, as well as factual summaries of
he potential uses of the test were distributed to the raters
online Appendix C and D at www.acc.org). Care was given to
rovide objective, non-biased information.
The panelists were asked to assess whether the use of CCT
nd CMR for various indications was appropriate, uncertain,
r inappropriate. In rating each indication, the panel was
rovided the following definition of appropriateness:
An appropriate imaging study is one in which the expected
ncremental information, combined with clinical judgment,
xceeds the expected negative consequences* by a sufficiently
ide margin for a specific indication that the procedure is
enerally considered acceptable care and a reasonable approach
or the indication.
*Negative consequences include the risks of the procedure (i.e.,
adiation or contrast exposure) and the downstream impact of
oor test performance such as delay in diagnosis (false negatives)
r inappropriate diagnosis (false positives).The Technical Panel scored each indication as follows:
Score 7 to 9
Appropriate test for specific indication (test is generally
acceptable and is a reasonable approach for the indi-
cation).
Score 4 to 6
Uncertain for specific indication (test may be generally
acceptable and may be a reasonable approach for the
indication). (Uncertainty also implies that more re-
search and/or patient information is needed to classify
the indication definitively.)
Score 1 to 3
Inappropriate test for that indication (test is not generally
acceptable and is not a reasonable approach for the
indication).
ESULTS OF RATINGS
he final ratings for CCT (Tables 1 to 8) and CMR (Tables
2 to 17) are listed by indication sequentially, by purpose and
linical scenario, as obtained from the second round rating
heets submitted by each panelist. In addition, Tables 9 to 11
nd 18 to 20 arrange the indications into 3 main scoring
ategories (appropriate [median score of 7 to 9], uncertain
median score of 4 to 6], and inappropriate [median score of 1
o 3]) for CCT and CMR, respectively. Other tables, including
ocumentation of the mean absolute deviation from the
edian and level of agreement for each indication, are found in
he online Appendices A and B at www.acc.org. Abbreviations
sed in the tables and the text of this report are listed below.
bbreviations
ACS  acute coronary syndromes
CABG  coronary artery bypass grafting surgery
CAD  coronary artery disease
CCT  cardiac computed tomography
CHD  coronary heart disease
CMR  cardiac magnetic resonance imaging
CT  computed tomography
EBCT  electron beam computed tomography
ECG  electrocardiogram
HF  heart failure
ICD-9  International Classification of Diseases-9th
Revision
LCD  local coverage determination
METs  estimated metabolic equivalents of exercise
MI  myocardial infarction
MPI  myocardial perfusion imaging
NSTEMI  non–ST-segment elevation myocardial
infarction
PCI  percutaneous coronary intervention
SPECT MPI  single-photon emission computed to-
mography myocardial perfusion imaging
STEMI  ST-segment elevation myocardial infarction
TEE  transesophageal echocardiography
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Assume the logical operator between each variable listed for an indication is “AND” unless otherwise noted
(e.g., Low pre-test probability of CAD AND No ECG changes and serial enzymes negative).
Table 1. Detection of CAD: Symptomatic
Indication
Appropriateness
Criteria
(Median Score)
Evaluation of Chest Pain Syndrome (Use of CT Angiogram)
1. ● Intermediate pre-test probability of CAD
● ECG interpretable AND able to exercise
U (5)
2. ● Intermediate pre-test probability of CAD
● ECG uninterpretable OR unable to exercise
A (7)
3. ● High pre-test probability of CAD I (2)
Evaluation of Intra-Cardiac Structures (Use of CT Angiogram)
4. ● Evaluation of suspected coronary anomalies A (9)
Acute Chest Pain (Use of CT Angiogram)
5. ● Low pre-test probability of CAD U (5)
● No ECG changes and serial enzymes negative
6. ● Intermediate pre-test probability of CAD A (7)
● No ECG changes and serial enzymes negative
7. ● High pre-test probability of CAD U (6)
● No ECG changes and serial enzymes negative
8. ● High pre-test probability of CAD I (1)
● ECG—ST-segment elevation and/or positive cardiac enzymes
9. ● “Triple rule out”—exclude obstructive CAD, aortic dissection,
and pulmonary embolism
U (4)
● Intermediate pre-test probability for one of the above
● ECG—no ST-segment elevation and initial enzymes negative
Table 2. Detection of CAD: Asymptomatic (Without Chest Pain Syndrome)
Indication
Appropriateness
Criteria
(Median Score)
Asymptomatic (Use of CT Angiogram)
10. ● Low CHD risk (Framingham risk criteria) I (1)
11. ● Moderate CHD risk (Framingham) I (2)
12. ● High CHD risk (Framingham) U (4)
Table 3. Risk Assessment: General Population
Indication
Appropriateness
Criteria
(Median Score)
Asymptomatic (Calcium Scoring)
13. ● Low CHD risk (Framingham) I (1)
14. ● Moderate CHD risk (Framingham) U (6)15. ● High CHD risk (Framingham) U (5)
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Appropriateness Criteria for CCT/CMR October 3, 2006:1475–97Table 4. Detection of CAD With Prior Test Results
Indication
Appropriateness
Criteria
(Median Score)
Evaluation of Chest Pain Syndrome (Use of CT Angiogram)
16. ● Uninterpretable or equivocal stress test (exercise, perfusion,
or stress echo)
A (8)
17. ● Evidence of moderate to severe ischemia on stress test I (2)
(exercise, perfusion, or stress echo)Table 5. Risk Assessment With Prior Test Results
Indication
Appropriateness
Criteria
(Median Score)
Asymptomatic (Calcium Scoring)
18. ● Prior calcium score within previous 5 years I (1)
Asymptomatic (Use of CT Angiogram)
19. ● High CHD risk (Framingham) I (2)
● Within 2 years prior cardiac CT angiogram or invasive angiogram
without significant obstructive disease
20. ● High CHD risk (Framingham) I (3)
● Prior calcium score greater than or equal to 400Table 6. Risk Assessment: Preoperative Evaluation for Non-Cardiac Surgery
Indication
Appropriateness
Criteria
(Median Score)
Low-Risk Surgery (Use of CT Angiogram)
21. ● Intermediate perioperative risk I (1)
Intermediate- or High-Risk Surgery (Use of CT Angiogram)22. ● Intermediate perioperative risk U (4)Table 7. Detection of CAD: Post-Revascularization (PCI or CABG)
Indication
Appropriateness
Criteria
(Median Score)
Evaluation of Chest Pain Syndrome (Use of CT Angiogram)
23. ● Evaluation of bypass grafts and coronary anatomy U (6)
24. ● History of percutaneous revascularization with stents U (5)
Asymptomatic (Use of CT Angiogram)
25. ● Evaluation of bypass grafts and coronary anatomy I (2)
● Less than 5 years after CABG
26. ● Evaluation of bypass grafts and coronary anatomy I (3)
● Greater than or equal to 5 years after CABG
27. ● Evaluation for in-stent restenosis and coronary anatomy after
PCI
I (2)
T*
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Indication
Appropriateness
Criteria
(Median Score)
Morphology (Use of CT Angiogram)
28. ● Assessment of complex congenital heart disease including anomalies of coronary circulation, great
vessels, and cardiac chambers and valves
A (7)
29. ● Evaluation of coronary arteries in patients with new onset heart failure to assess etiology A (7)
Evaluation of Ventricular and Valvular Function (Use of CT Angiogram)
30. ● Evaluation of LV function following myocardial infarction OR in heart failure patients I (3)
31. ● Evaluation of LV function following myocardial infarction OR in heart failure patients U (5)
● Patients with technically limited images from echocardiogram
32. ● Characterization of native and prosthetic cardiac valves U (5)
● Patients with technically limited images from echocardiogram, MRI, or TEE
Evaluation of Intra- and Extra-Cardiac Structures (Use of Cardiac CT)
33. ● Evaluation of cardiac mass (suspected tumor or thrombus) A (8)
● Patients with technically limited images from echocardiogram, MRI, or TEE
34. ● Evaluation of pericardial conditions (pericardial mass, constrictive pericarditis, or complications of
cardiac surgery)
A (8)
● Patients with technically limited images from echocardiogram, MRI, or TEE
35. ● Evaluation of pulmonary vein anatomy prior to invasive radiofrequency ablation for atrial fibrillation A (8)
36. ● Noninvasive coronary vein mapping prior to placement of biventricular pacemaker A (8)
37. ● Noninvasive coronary arterial mapping, including internal mammary artery prior to repeat cardiac
surgical revascularization
A (8)
Evaluation of Aortic and Pulmonary Disease (Use of CT Angiogram*)
38. ● Evaluation of suspected aortic dissection or thoracic aortic aneurysm A (9)
39. ● Evaluation of suspected pulmonary embolism A (9)
Non-gated, CT angiogram which has a sufficiently large field of view for these specific indications.
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able 9. Inappropriate Indications (Median Score 1–3)
Indication
Appropriateness
Criteria
(Median Score)
Detection of CAD: Symptomatic—Evaluation of Chest Pain Syndrome (Use of CT Angiogram)
3. ● High pre-test probability of CAD I (2)
Detection of CAD: Symptomatic—Acute Chest Pain (Use of CT Angiogram)
8. ● High pre-test probability of CAD I (1)
● ECG—ST-segment elevation and/or positive cardiac enzymes
Detection of CAD: Asymptomatic (Without Chest Pain Syndrome)—Asymptomatic (Use of CT Angiogram)
10. ● Low CHD risk (Framingham risk criteria) I (1)
11. ● Moderate CHD risk (Framingham) I (2)
Risk Assessment: General Population—Asymptomatic (Calcium Scoring)
13. ● Low CHD risk (Framingham) I (1)
Detection of CAD With Prior Test Results—Evaluation of Chest Pain Syndrome (Use of CT Angiogram)
17. ● Evidence of moderate to severe ischemia on stress test (exercise, perfusion, or stress echo) I (2)
Risk Assessment With Prior Test Results—Asymptomatic (Calcium Scoring)
18. ● Prior calcium score within previous 5 years I (1)
Risk Assessment With Prior Test Results—Asymptomatic (Use of CT Angiogram)
19. ● High CHD risk (Framingham) I (2)
● Within 2 years prior cardiac CT angiogram or invasive angiogram without significant obstructive disease
20. ● High CHD risk (Framingham) I (3)
● Prior calcium score greater than or equal to 400
Risk Assessment: Preoperative Evaluation for Non-Cardiac Surgery—Low-Risk Surgery (Use of CT Angiogram)
21. ● Intermediate perioperative risk I (1)
Detection of CAD: Post-Revascularization (PCI or CABG)—Asymptomatic (Use of CT Angiogram)
25. ● Evaluation of bypass grafts and coronary anatomy I (2)
● Less than 5 years after CABG
26. ● Evaluation of bypass grafts and coronary anatomy I (3)
● Greater than or equal to 5 years after CABG
27. ● Evaluation for in-stent restenosis and coronary anatomy after PCI I (2)
Structure and Function—Evaluation of Ventricular and Valvular Function (Use of CT Angiogram)
30. ● Evaluation of LV function following myocardial infarction OR in heart failure patients I (3)
T*
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Indication
Appropriateness
Criteria
(Median Score)
Detection of CAD: Symptomatic—Evaluation of Chest Pain Syndrome (Use of CT Angiogram)
2. ● Intermediate pre-test probability of CAD A (7)
● ECG uninterpretable OR unable to exercise
Detection of CAD: Symptomatic—Evaluation of Intra-Cardiac Structures (Use of CT Angiogram)
4. ● Evaluation of suspected coronary anomalies A (9)
Detection of CAD: Symptomatic—Acute Chest Pain (Use of CT Angiogram)
6. ● Intermediate pre-test probability of CAD A (7)
● No ECG changes and serial enzymes negative
Detection of CAD With Prior Test Results—Evaluation of Chest Pain Syndrome (Use of CT Angiogram)
16. ● Uninterpretable or equivocal stress test (exercise, perfusion, or stress echo) A (8)
Structure and Function—Morphology (Use of CT Angiogram)
28. ● Assessment of complex congenital heart disease including anomalies of coronary circulation, great
vessels, and cardiac chambers and valves
A (7)
29. ● Evaluation of coronary arteries in patients with new onset heart failure to assess etiology A (7)
Structure and Function—Evaluation of Intra- and Extra-Cardiac Structures (Use of Cardiac CT)
33. ● Evaluation of cardiac mass (suspected tumor or thrombus) A (8)
● Patients with technically limited images from echocardiogram, MRI, or TEE
34. ● Evaluation of pericardial conditions (pericardial mass, constrictive pericarditis, or complications of
cardiac surgery)
A (8)
● Patients with technically limited images from echocardiogram, MRI, or TEE
35. ● Evaluation of pulmonary vein anatomy prior to invasive radiofrequency ablation for atrial fibrillation A (8)
36. ● Noninvasive coronary vein mapping prior to placement of biventricular pacemaker A (8)
37. ● Noninvasive coronary arterial mapping, including internal mammary artery prior to repeat cardiac
surgical revascularization
A (8)
Structure and Function—Evaluation of Aortic and Pulmonary Disease (Use of CT Angiogram*)
38. ● Evaluation of suspected aortic dissection or thoracic aortic aneurysm A (9)
39. ● Evaluation of suspected pulmonary embolism A (9)
Non-gated, CT angiogram which has a sufficiently large field of view for these specific indications.
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Indication
Appropriateness
Criteria
(Median Score)
Detection of CAD: Symptomatic—Evaluation of Chest Pain Syndrome (Use of CT Angiogram)
1. ● Intermediate pre-test probability of CAD U (5)
● ECG interpretable AND able to exercise
Detection of CAD: Symptomatic—Acute Chest Pain (Use of CT Angiogram)
5. ● Low pre-test probability of CAD U (5)
● No ECG changes and serial enzymes negative
7. ● High pre-test probability of CAD U (6)
● No ECG changes and serial enzymes negative
9. ● “Triple rule out”—exclude obstructive CAD, aortic dissection, and pulmonary embolism U (4)
● Intermediate pre-test probability for one of the above
● ECG—no ST-segment elevation and initial enzymes negative
Detection of CAD: Asymptomatic (Without Chest Pain Syndrome)—Asymptomatic (Use of CT Angiogram)
12. ● High CHD risk (Framingham) U (4)
Risk Assessment: General Population—Asymptomatic (Calcium Scoring)
14. ● Moderate CHD risk (Framingham) U (6)
15. ● High CHD risk (Framingham) U (5)
Risk Assessment: Preoperative Evaluation for Non-Cardiac Surgery—Intermediate or High Risk Surgery (Use of CT Angiogram)
22. ● Intermediate perioperative risk U (4)
Detection of CAD: Post-Revascularization (PCI or CABG)—Evaluation of Chest Pain Syndrome (Use of CT Angiogram)
23. ● Evaluation of bypass grafts and coronary anatomy U (6)
24. ● History of percutaneous revascularization with stents U (5)
Structure and Function—Evaluation of Ventricular and Valvular Function (Use of CT Angiogram)
31. ● Evaluation of LV function following myocardial infarction OR in heart failure patients U (5)
● Patients with technically limited images from echocardiogram
32. ● Characterization of native and prosthetic cardiac valves U (5)
● Patients with technically limited images from echocardiogram, MRI, or TEE
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Assume the logical operator between each variable listed for an indication is “AND” unless otherwise noted
(e.g., Low pre-test probability of CAD AND No ECG changes and serial enzymes negative).
Table 12. Detection of CAD: Symptomatic
Indication
Appropriateness
Criteria
(Median Score)
Evaluation of Chest Pain Syndrome (Use of Vasodilator Perfusion CMR
or Dobutamine Stress Function CMR)
1. ● Low pre-test probability of CAD I (2)
● ECG interpretable AND able to exercise
2. ● Intermediate pre-test probability of CAD U (4)
● ECG interpretable AND able to exercise
3. ● Intermediate pre-test probability of CAD A (7)
● ECG uninterpretable OR unable to exercise
4. ● High pre-test probability of CAD U (5)
Evaluation of Chest Pain Syndrome (Use of MR Coronary Angiography)
5. ● Intermediate pre-test probability of CAD I (2)
● ECG interpretable AND able to exercise
6. ● Intermediate pre-test probability of CAD I (2)
● ECG uninterpretable OR unable to exercise
7. ● High pre-test probability of CAD I (1)
Evaluation of Intra-Cardiac Structures (Use of MR Coronary Angiography)
8. ● Evaluation of suspected coronary anomalies A (8)
Acute Chest Pain (Use of Vasodilator Perfusion CMR or Dobutamine Stress Function CMR)
9. ● Intermediate pre-test probability of CAD U (6)
● No ECG changes and serial cardiac enzymes negative
10. ● High pre-test probability of CAD I (1)
● ECG—ST-segment elevation and/or positive cardiac enzymes
Table 13. Risk Assessment With Prior Test Results (Use of Vasodilator Perfusion CMR or
Dobutamine Stress Function CMR)
Indication
Appropriateness
Criteria
(Median Score)
11. ● Normal prior stress test (exercise, nuclear, echo, MRI) I (2)
● High CHD risk (Framingham)
● Within 1 year of prior stress test
12. ● Equivocal stress test (exercise, stress SPECT, or stress echo) U (6)
● Intermediate CHD risk (Framingham)
13. ● Coronary angiography (catheterization or CT) A (7)
● Stenosis of unclear significance
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Indication
Appropriateness
Criteria
(Median Score)
Low-Risk Surgery (Use of Vasodilator Perfusion CMR or Dobutamine Stress Function CMR)
14. ● Intermediate perioperative risk predictor I (2)
Intermediate- or High-Risk Surgery (Use of Vasodilator Perfusion CMR
or Dobutamine Stress Function CMR)15. ● Intermediate perioperative risk predictor U (6)Table 15. Detection of CAD: Post-Revascularization (PCI or CABG)
Indication
Appropriateness
Criteria
(Median Score)
Evaluation of Chest Pain Syndrome (Use of MR Coronary Angiography)
16. ● Evaluation of bypass grafts I (2)17. ● History of percutaneous revascularization with stents I (1)able 16. Structure and Function
Indication
Appropriateness
Criteria
(Median Score)
Evaluation of Ventricular and Valvular Function
Procedures may include LV/RV mass and volumes, MR angiography, quantification of valvular disease, and delayed contrast enhancement
18. ● Assessment of complex congenital heart disease including anomalies of coronary circulation,
great vessels, and cardiac chambers and valves
A (9)
● Procedures may include LV/RV mass and volumes, MR angiography, quantification of valvular
disease, and contrast enhancement
19. ● Evaluation of LV function following myocardial infarction OR in heart failure patients U (6)
20. ● Evaluation of LV function following myocardial infarction OR in heart failure patients A (8)
● Patients with technically limited images from echocardiogram
21. ● Quantification of LV function A (8)
● Discordant information that is clinically significant from prior tests
22. ● Evaluation of specific cardiomyopathies (infiltrative [amyloid, sarcoid], HCM, or due to
cardiotoxic therapies)
A (8)
● Use of delayed enhancement
23. ● Characterization of native and prosthetic cardiac valves—including planimetry of stenotic
disease and quantification of regurgitant disease
A (8)
● Patients with technically limited images from echocardiogram or TEE
24. ● Evaluation for arrythmogenic right ventricular cardiomyopathy (ARVC) A (9)
● Patients presenting with syncope or ventricular arrhythmia
25. ● Evaluation of myocarditis or myocardial infarction with normal coronary arteries A (8)
● Positive cardiac enzymes without obstructive atherosclerosis on angiography
Evaluation of Intra- and Extra-Cardiac Structures
26. ● Evaluation of cardiac mass (suspected tumor or thrombus) A (9)
● Use of contrast for perfusion and enhancement
27. ● Evaluation of pericardial conditions (pericardial mass, constrictive pericarditis) A (8)
28. ● Evaluation for aortic dissection A (8)
29. ● Evaluation of pulmonary veins prior to radiofrequency ablation for atrial fibrillation A (8)
● Left atrial and pulmonary venous anatomy including dimensions of veins for mapping purposes
TT
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Indication
Appropriateness
Criteria
(Median Score)
Evaluation of Myocardial Scar (Use of Late Gadolinium Enhancement)
30. ● To determine the location and extent of myocardial necrosis including ‘no reflow’ regions A (7)
● Post-acute myocardial infarction
31. ● To detect post PCI myocardial necrosis U (4)
32. ● To determine viability prior to revascularization A (9)
● Establish likelihood of recovery of function with revascularization (PCI or CABG) or medical therapy
33. ● To determine viability prior to revascularization A (9)
● Viability assessment by SPECT or dobutamine echo has provided “equivocal or indeterminate” resultsCMR APPROPRIATENESS CRITERIA (BY APPROPRIATENESS CATEGORY)able 18. Inappropriate Indications (Median Score 1–3)
Indication
Appropriateness
Criteria
(Median Score)
Detection of CAD: Symptomatic—Evaluation of Chest Pain Syndrome (Use of Vasodilator Perfusion CMR
or Dobutamine Stress Function CMR)
1. ● Low pre-test probability of CAD I (2)
● ECG interpretable AND able to exercise
Detection of CAD: Symptomatic—Evaluation of Chest Pain Syndrome (Use of MR Coronary Angiography)
5. ● Intermediate pre-test probability of CAD I (2)
● ECG interpretable AND able to exercise
6. ● Intermediate pre-test probability of CAD I (2)
● ECG uninterpretable OR unable to exercise
7. ● High pre-test probability of CAD I (1)
Detection of CAD: Symptomatic—Acute Chest Pain (Use of Vasodilator Perfusion CMR or Dobutamine Stress Function CMR)
10. ● High pre-test probability of CAD I (1)
● ECG—ST-segment elevation and/or positive cardiac enzymes
Risk Assessment With Prior Test Results (Use of Vasodilator Perfusion CMR or Dobutamine Stress Function CMR)
11. ● Normal prior stress test (exercise, nuclear, echo, MRI) I (2)
● High CHD risk (Framingham)
● Within 1 year of prior stress test
Risk Assessment: Preoperative Evaluation for Non-Cardiac Surgery—Low Risk Surgery
(Use of Vasodilator Perfusion CMR or Dobutamine Stress Function CMR)
14. ● Intermediate perioperative risk predictor I (2)
Detection of CAD: Post-Revascularization (PCI or CABG)—Evaluation of Chest Pain Syndrome
(Use of MR Coronary Angiography)
16. ● Evaluation of bypass grafts I (2)
17. ● History of percutaneous revascularization with stents I (1)
T1488 Hendel et al. JACC Vol. 48, No. 7, 2006
Appropriateness Criteria for CCT/CMR October 3, 2006:1475–97able 19. Appropriate Indications (Median Score 7–9)
Indication
Appropriateness
Criteria
(Median Score)
Detection of CAD: Symptomatic—Evaluation of Chest Pain Syndrome (Use of Vasodilator Perfusion CMR
or Dobutamine Stress Function CMR)
3. ● Intermediate pre-test probability of CAD A (7)
● ECG uninterpretable OR unable to exercise
Detection of CAD: Symptomatic—Evaluation of Intra-Cardiac Structures (Use of MR Coronary Angiography)
8. ● Evaluation of suspected coronary anomalies A (8)
Risk Assessment With Prior Test Results (Use of Vasodilator Perfusion CMR or Dobutamine Stress Function CMR)
13. ● Coronary angiography (catheterization or CT) A (7)
● Stenosis of unclear significance
Structure and Function—Evaluation of Ventricular and Valvular Function
Procedures may include LV/RV mass and volumes, MR angiography, quantification of valvular disease, and delayed contrast enhancement
18. ● Assessment of complex congenital heart disease including anomalies of coronary circulation, great vessels,
and cardiac chambers and valves
A (9)
● Procedures may include LV/RV mass and volumes, MR angiography, quantification of valvular disease, and
contrast enhancement
20. ● Evaluation of LV function following myocardial infarction OR in heart failure patients A (8)
● Patients with technically limited images from echocardiogram
21. ● Quantification of LV function A (8)
● Discordant information that is clinically significant from prior tests
22. ● Evaluation of specific cardiomyopathies (infiltrative [amyloid, sarcoid], HCM, or due to cardiotoxic
therapies)
A (8)
● Use of delayed enhancement
23. ● Characterization of native and prosthetic cardiac valves—including planimetry of stenotic disease and
quantification of regurgitant disease
A (8)
● Patients with technically limited images from echocardiogram or TEE
24. ● Evaluation for arrythmogenic right ventricular cardiomyopathy (ARVC) A (9)
● Patients presenting with syncope or ventricular arrhythmia
25. ● Evaluation of myocarditis or myocardial infarction with normal coronary arteries A (8)
● Positive cardiac enzymes without obstructive atherosclerosis on angiography
Structure and Function—Evaluation of Intra- and Extra-Cardiac Structures
26. ● Evaluation of cardiac mass (suspected tumor or thrombus) A (9)
● Use of contrast for perfusion and enhancement
27. ● Evaluation of pericardial conditions (pericardial mass, constrictive pericarditis) A (8)
28. ● Evaluation for aortic dissection A (8)
29. ● Evaluation of pulmonary veins prior to radiofrequency ablation for atrial fibrillation A (8)
● Left atrial and pulmonary venous anatomy including dimensions of veins for mapping purposes
Detection of Myocardial Scar and Viability—Evaluation of Myocardial Scar (Use of Late Gadolinium Enhancement)
30. ● To determine the location, and extent of myocardial necrosis including ‘no reflow’ regions A (7)
● Post acute myocardial infarction
32. ● To determine viability prior to revascularization A (9)
● Establish likelihood of recovery of function with revascularization (PCI or CABG) or medical therapy
33. ● To determine viability prior to revascularization A (9)
● Viability assessment by SPECT or dobutamine echo has provided “equivocal or indeterminate” results
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he indications contained in this report were selected to
over a wide variety of clinical presentations. They are based
n common patient presentations such as symptoms sug-
estive of ischemia, multiple cardiac risk factors in an
symptomatic individual, and specific scenarios with indices
f high clinical suspicion that are further stratified based on
actors such as clinical risk, prior test results, and the interval
ince prior testing. The purpose of this approach is to
elineate the possible value of CCT or CMR for a physician
aced with everyday patient scenarios. The indications do
ot correspond directly to International Classification of
iseases-9th Revision (ICD-9) codes, as they convey more
nformation than usually found in the ICD-9 classification
ystem. Some correlation with previous model local cover-
ge determination (LCD) documents is purposeful, but the
ndications are designed to provide further guidance within
he categories outlined in the model LCD for ordering
hysicians. It is recognized that not all categories within an
CD or for ICD-9 codes are represented.
The appropriateness criteria for CCT and CMR are 2
eparate reports and were not developed in a way that can
rovide comparative information about the utility of one
est versus the other. Although the same panel ranked the
ndications for both CCT and CMR, members of the
echnical Panel were asked specifically NOT to compara-
ively rank each of these imaging procedures, but instead to
able 20. Uncertain Indications (Median Score 4–6)
Indication
Detection of CAD: Symptomatic—Evaluation of C
or Dobutamine
2. ● Intermediate pre-test probability of CAD
● ECG interpretable AND able to exercise
4. ● High pre-test probability of CAD
Detection of CAD: Symptomatic—Acute Chest Pain (Use of V
9. ● Intermediate pre-test probability of CAD
● No ECG changes and serial cardiac enzymes negat
Risk Assessment With Prior Test Results (Use of Vasodi
12. ● Equivocal stress test (exercise, stress SPECT, or st
● Intermediate CHD risk (Framingham)
Risk Assessment: Preoperative Evaluation for Non
(Use of Vasodilator Perfusion CM
15. ● Intermediate perioperative risk predictor
Structure and Function—Evaluatio
Procedures may include LV/RV mass and volumes, MR angiograp
19. ● Evaluation of LV function following myocardial in
Evaluation of Myocardial Scar (U
31. ● To detect post PCI myocardial necrosisonsider each test on its own merits. As such, the scores and phe conclusions about appropriateness also should not be
ompared with the prior report for appropriateness for
ingle-photon emission computed tomography myocardial
erfusion imaging (SPECT MPI) (8) or to those soon to be
ritten for other imaging procedures, such as echocardiog-
aphy.
For the 39 indications for CCT, 13 were found to be
ppropriate, and 12 were uncertain. Fourteen of these
ndications were felt to be inappropriate reasons for CT test
erformance. There was great variability in scores for the
ncertain category, suggesting markedly differing opinions.
owever, there was substantial agreement as defined by
AND (9) for a panel this size for the categories labeled as
ither appropriate or inappropriate, with 77% and 86%,
espectively, showing agreement. Cardiac computed tomog-
aphy was considered reasonable for a number of scenarios
eyond assessments of structure and function, but still over
0% of the indications were for this area.
For CMR, 17 of the 33 indications were ranked as
ppropriate, with another 7 being uncertain. Nine scenarios
ere considered to be inappropriate reasons for magnetic
esonance test performance. Similar to the indications for
CT, uncertain scenarios showed wider dispersion of scores
han those for indications at either end of the spectrum.
greement, as defined for a panel this size by RAND (9),
as present for 82% of the appropriate indications and 89%
or those felt to be inappropriate. Two-thirds of the appro-
Appropriateness
Criteria
(Median Score)
ain Syndrome (Use of Vasodilator Perfusion CMR
Function CMR)
U (4)
U (5)
ilator Perfusion CMR or Dobutamine Stress Function CMR)
U (6)
Perfusion CMR or Dobutamine Stress Function CMR)
ho) U (6)
diac Surgery—Intermediate or High Risk Surgery
Dobutamine Stress Function CMR)
U (6)
Ventricular and Valvular Function
antification of valvular disease, and delayed contrast enhancement
n OR in heart failure patients U (6)
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he strengths of CMR as a tool for defining the etiology of
omplex patient presentations where the clinical suspicion is
igh. The scores for other uses reflect the evolving nature of
he capabilities of the test.
The indications contained in this report are not exhaus-
ive. For example, the use of CCT or CMR for the
on-invasive evaluation of coronary arteries before non-
oronary cardiac surgery was not listed as an indication,
lthough this may be an evolving application. Additionally,
here may be medical reasons that would preclude the
pplication of the appropriateness criteria to a specific
atient, and clinician judgment should be used at all times
n the application of these criteria. Furthermore, the local
vailability or quality of equipment or personnel may influ-
nce the selection of appropriate imaging procedures. Ap-
ropriateness criteria, in other words, are not substitutes for
ound clinical judgment and practice experience with each
atient and clinical presentation. For example, the rating of
n indication as inappropriate should not preclude a pro-
ider from performing CCT or CMR procedures when
here are patient- and condition-specific data to support
hat decision. Conversely, not doing a study that is deemed
ppropriate may be the correct decision in light of unique
atient, clinical, and other relevant information.
The category of “uncertain” was discussed at length by the
echnical Panel and the Working Group. The consensus of
he Panel was that this intermediate level of appropriateness
hould be labeled “uncertain,” as either critical data were
acking or significant differences of opinion exist among
anel members regarding the value of the method for that
articular indication. The categorization of a particular
ndication as uncertain should serve as a nidus for additional
nformation and research so as to formulate a definitive level
f appropriateness.
The primary objective of this report is to provide guid-
nce regarding the perceived suitability of CCT and CMR
or diverse clinical scenarios. As with the Appropriateness
riteria for SPECT MPI (8), consensus among the raters
as desirable, but achievement of complete agreement
ithin this diverse panel would have been artificial and not
ecessarily of clinical value. Two rounds of rating with
ntervening discussion did lead to some consensus. How-
ver, further attempts to drive consensus might have artifi-
ially diluted true differences in opinion among panelists.
his is especially true for both CCT and CMR, as these are
till emerging clinical imaging modalities with an evolving
vidence base.
The appropriateness criteria in these reports are expected
o be useful for clinicians, health care facilities, and third-
arty payers in the delivery of quality cardiovascular imag-
ng. For example, individual clinicians could use the ratings
s a supportive decision or educational tool when ordering a
est or providing a referral to another qualified physician.
he criteria also may be used to respond to a referring
hysician who has ordered a test for an inappropriate cndication. Facilities and payers can use the criteria either
rospectively in the design of protocols and pre-
uthorization procedures or retrospectively for quality re-
orts. It is hoped that payers will use this document as the
asis for their own strategies to ensure that their members
eceive quality, but cost-effective, cardiovascular care.
When used for accountability, appropriateness criteria
hould be used in conjunction with systems that support
uality improvement. Prospective pre-authorization proce-
ures, for example, may be used most effectively once a
etrospective review has identified a pattern of potential
nappropriate use. Because the criteria are based on up-to-
ate scientific evidence and the deliberations of the Tech-
ical Panel, they can be used to help resolve future reim-
ursement cases or appeals but should not be applied to
ases completed before issuance of this report.
The linking of indications rated as generally acceptable
ractice with analysis of related patient outcomes, and a
eview of what is “necessary” care, will improve understand-
ng of regional variations in imaging and the potential for
nsuring the equitable and efficient allocation of resources
or diagnostic studies. Further exploration of the indications
hat are rated as “uncertain” will generate new empirical
esearch and the data required to further define the appro-
riateness of CCT and CMR. Finally, periodic assessment
nd updating of the indications and criteria will be required
s new data and field experience become available.
PPENDIX A: METHODS
anel Selection
n initial list of potential Technical Panel members was
enerated based on a call for nominations issued to all
elevant stakeholders. Panel members were selected by the
orking Group in a manner that ensured an appropriate
alance with respect to expertise in the specific modality,
cademic versus private practice, health services research,
nd specialty training.
evelopment of Indications
he process for creating a robust set of indications involved
onsulting current literature, previously published state-
ents, and model local coverage determination documents.
he indications capture the majority of scenarios faced by
ardiologists or referring physicians, but are not meant to be
nclusive of all potential indications for which CCT or
MR imaging studies may be performed. Review was done
y the Working Group, including additional comments
rom external reviewers. As a result of the meeting of the
echnical Panel before the second round of rating, a few of
he indications were clarified and modified. A final set of
ndications comprised the list of possible clinical scenarios
hat were rated for appropriateness by the panelists and
ompiled for this report.
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ll indications for CCT and CMR were considered with
he following important assumptions:
. All indications should first be evaluated based on the
available medical literature. In many cases, studies are
reflections of the capabilities and limitations of the test
but provide minimal information about the role of the
test in clinical decision making. Appropriateness criteria
development requires determination of a reasonable
course of action for clinical decision making based on a
risk/benefit trade-off as determined by individual pa-
tient indications.
. Cost SHOULD be considered implicitly in the appro-
priateness determination.
. Risks, such as radiation exposure and contrast adverse
effects, should be considered.
. Additional factors may be considered implicitly in the
appropriateness determination including the impact of
the image on clinical decision making when combined
with clinical judgment.
. For each indication, the panelists’ ratings should reflect
whether the test is reasonable for the patient according
to the appropriateness definition, not whether the test
is better or worse than another. It also should not
consider issues of local availability or skill for any
modality or variation in equipment. It should be as-
sumed that the imaging procedure will be performed in
accordance with best practice, using appropriate equip-
ment and techniques.
. Specific comparisons with previous sets of appropriate-
ness criteria should not be made.
. All techniques are assumed to be performed in an optimal
fashion, using appropriate equipment and protocols.
. The test is assumed to be performed by a qualified
individual in a facility that is proficient in the imaging
technique.
ssumptions for CCT only:
. Cardiac computed tomography imaging equipment and
personnel are available that have the minimal technical
capabilities required for the indication (the number of
detector rows, spatial and temporal resolution, and ac-
quisition protocols).
. Indications for CT angiography assume that calcium
scoring also may be obtained for that indication.
. Calcium scoring is assumed to be performed by EBCT
or multislice CT.
. Unless specifically noted, use of the test to determine non-
cardiac etiologies for an indication is not considered.
. For CT angiography, patients are assumed not to present
with any of the following:
a. Irregular rhythm (e.g., atrial fibrillation/flutter, fre-
quent irregular premature ventricular contractions or
premature atrial contractions, and high grade heart
block); rb. Very obese patients, body mass index greater than 40
kg/m2;
c. Renal insufficiency, creatinine greater than 1.8 mg/
dL;
d. Heart rate greater than 70 beats/min refractory to
heart-rate-lowering agents (e.g., a combination of
beta-blocker and calcium-channel blocker);
e. Metallic interference (e.g., surgical clips, pacemaker,
and/or defibrillator wires, or tissue expander.
. For CT angiography, patients must be able to:
a. Hold still;
b. Follow breathing instruction;
c. Take nitroglycerin (for performing coronary CT an-
giography only);
d. Take iodine in spite of steroid prep for contrast
allergy;
e. Lift both arms above the shoulders.
ote: Any patient presenting with the characteristics listed
n 5 and 6 above is assumed to be excluded from the
ndications for scoring purposes.
ssumptions for CMR only:
. Cardiac magnetic resonance imaging equipment and
personnel are available that have the minimal technical
capabilities required for the indication.
. Images are obtained with at least a 1.5-T magnet using
standard sequences provided by the current vendors.
. Use of gadolinium contrast is assumed for studies involv-
ing perfusion, angiograms, and contrast enhancement.
. Patients are assumed not to present with general CMR
imaging contraindications examples of which include:
a. severe claustrophobia;
b. specific metallic contraindications such as pacemak-
ers, defibrillators, and certain aneurysm clips.
ote: Studies are ongoing with regards to pacemakers and
mplantable defibrillators. In April 2005, the Food and
rug Administration approved magnetic resonance imaging
tudies immediately after implantation of sirolimus- and
aclitaxel-eluting stents, which is now reflected in the
espective package instructions for use.
ating Process
he Technical Panel was instructed to follow the process
utlined in the article previously published by the College
ntitled, “ACCF Proposed Method for Evaluating the
ppropriateness of Cardiovascular Imaging” (2). The ap-
ropriateness method combines expert clinical judgment
ith the scientific literature in evaluating the benefits and
isks of medical procedures. Ratings of the net benefits and
isks of performing medical procedures for a comprehensive
rray of potential patient indications or scenarios are ob-
ained from a multidisciplinary panel of expert clinicians.
ach panel member has equal weight in producing the finalesult, and the method does not force consensus.
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Appropriateness Criteria for CCT/CMR October 3, 2006:1475–97The rating process includes a modified Delphi process
nvolving 2 rounds of ratings and an intervening face-to-
ace meeting. The first round of ratings was completed
ndividually with no interaction among panel members. The
anel was then convened for a face-to-face meeting that was
acilitated by a moderator. The goal of the meeting was to
ocus discussion on indications for which the first round
cores of the panel were widely divergent. The objective of
he meeting was to allow all views to be heard. The second
ound ratings were conducted individually subsequent to the
ace-to-face meeting. The second round ratings were used
o determine the final appropriateness score based on the
edian score for each indication.
At the face-to-face meeting, each panelist received a
ersonalized rating form that indicated his/her rating for
ach indication and the distribution of ratings of other
embers of the panel, but without personal identification.
n addition, the moderator received a summary rating form
ith similar information (including panelist identification),
long with other statistics that measured the level of
greement among panel members. A measure of the level of
isagreement was applied to each score after both the first
nd second round scoring was completed. This project
mployed the BIOMED Concerted Action on Appropri-
teness definition for a panel size of 14 to 16. As defined in
he RAND/UCLA manual (9) upon which the ACCF
atings method is based, the BIOMED rule for agreement
) is that no more than 4 panelists rate the indication
utside the 3-point region containing the median; for
isagreement (), at least 5 panelists rate in each extreme
ating region (i.e., 1 to 3 and 7 to 9). Measures of agreement
nd the dispersion of ratings (mean absolute deviation from
he median) may highlight areas where definitions are not
lear or ratings are inconsistent, where panelist perceptions
f the “average” patient may differ, or where various spe-
ialty groups or individual panelists may have differences of
linical opinion. In cases of obvious disagreement or outlier
cores, the indication was highlighted in a summary table
nd identification of the outlier raters brought to the
ttention of the moderator. This information was used by
he moderator to guide the panel’s discussion.
elationships With Industry
he College and its partnering organizations rigorously avoid
ny actual, perceived, or potential conflicts of interest that
ight arise as a result of an outside relationship or personal
nterest of a member of the Technical Panel. Specifically, all
anelists are asked to provide disclosure statements of all
elationships that might be perceived as real or potential
onflicts of interest. These statements were reviewed by the
ppropriateness Criteria Working Group, discussed with all
embers of the Technical Panel at the face-to-face meeting,
nd updated and reviewed as necessary. A table of disclosures
y each Technical Panel and Oversight Working Group
ember can be found in Appendix D. titerature Review
he Technical Panel members were asked to refer to the
iterature summary, evidence tables, and reference list pro-
ided for each modality when completing their ratings
online Appendix C and D at www.acc.org). A paper
ecently published on clinical indications for CMR (10) also
as provided. Lastly, they were given the previously pub-
ished materials pertaining to the appropriateness criteria
ork (2,8).
PPENDIX B: DEFINITIONS AND PROCESSES FOR
ETERMINING LIKELIHOOD OF DISEASE AND RISK
etermining Pre-Test Probability of CAD
hest Pain Syndrome: Any constellation of symptoms that
he physician feels may represent a complaint consistent
ith obstructive CAD. Examples of such symptoms in-
lude, but are not exclusive to: chest pain, chest tightness,
urning, dyspnea, shoulder pain, and jaw pain.
Pre-Test Probability of CAD: Once the physician
etermines the presence of symptoms that may represent
bstructive CAD (chest pain syndrome present), then the
re-test probability of CAD should be determined.
Although there are several methods for determining
re-test probability of CAD (3,4), the method assumed for
his report is a modification of a literature review (5)
ecommended by the American College of Cardiology/
merican Heart Association (ACC/AHA) 2002 Guideline
pdate for Exercise Testing (11) and ACC/AHA 2002
uideline Update for Management of Patients with
hronic Stable Angina (12). The reader should refer to the
efinitions of angina and Table B1.
Angina: As defined by the ACC/AHA 2002 Guideline
pdate on Exercise Testing (11):
Typical Angina (Definite): 1) Substernal chest pain or
discomfort that is 2) provoked by exertion or emotional
stress and 3) relieved by rest and/or nitroglycerin (6).
Atypical Angina (Probable): Chest pain or discomfort
that lacks one of the characteristics of definite or typical
angina (6).
Non-Anginal Chest Pain: Chest pain or discomfort that
meets one or none of the typical angina characteristics.
etermining Pre-Test Risk
ssessment for Risk Stratification
isk Assessment The rating sheets on risk assessment
nclude indications in patients with suspected CAD. This
ssessment is particularly valuable in the setting of asymp-
omatic individuals.
It is assumed that clinicians will use imaging studies in
ddition to standard methods of risk assessment as presented in
he ACC/AHA Scientific Statement: Assessment of Cardio-
ascular Risk by Use of Multiple-Risk-Factor Assessment
quations (7), see Tables B2 and B3. Numerous discussions ofhe Framingham Risk Score calculation can be found online
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eb site: http://www.nhlbi.nih.gov/about/framingham/
iskabs.htm).
oronary Heart Disease (CHD) Risk
CHD Risk—Low
Defined by the age-specific risk level that is below
average. In general, low risk will correlate with a 10-year
absolute CHD risk less than 10%.
CHD Risk—Moderate
Defined by the age-specific risk level that is average or
above average. In general, moderate risk will correlate
with a 10-year absolute CHD risk between 10% and
20%.
able B1. Pre-Test Probability of CAD by Age, Gender, and Sy
Age (yrs) Gender
Typical/Definite
Angina Pectoris
30–39 Men Intermediate
Women Intermediate
40–49 Men High
Women Intermediate
50–59 Men High
Women Intermediate
60–69 Men High
Women High
igh: Greater than 90% pre-test probability; Intermediate: Between 10% and 90% p
% pre-test probability. *No data exist for patients less than 30 years or greater than
atients with ages at the extremes of the decades listed may have probabilities slight
Reproduced with permission from ACC/AHA 2002 Guideline Update for Exerc
Table B2. Men: 10-Year CHD Risk Accordin
*Low-risk level is defined in the Framingham Report as the r
non-diabetic, with blood pressure less than 120/80 mmHg,
and HDL-C greater than or equal to 45 mg/dL in men and
of points estimated from ACC/AHA Scientific Statement: A
Assessment Equations, Table 4 (7). ‡Total Coronary Hear
unrecognized myocardial infarction, unstable angina, and CH
for angina pectoris. Reprinted with permission from Grun
statement: assessment of cardiovascular risk by use of mult
professionals from the American Heart Association and the Ame
1348–59 (7).CHD Risk—High
Defined as the presence of diabetes mellitus or the
10-year absolute CHD risk of greater than 20%.
valuating Perioperative Risk for Non-Cardiac Surgery
ethod for Determining Perioperative Risk Periopera-
ive risk was determined for this report using a “Stepwise
pproach to Preoperative Cardiac Assessment,” found in
he ACC/AHA 2002 Guideline Update for Perioperative
ardiovascular Evaluation for Noncardiac Surgery (13).
ased on that algorithm, once it is determined that the
atient does not require urgent surgery, and that there
as not been revascularization within the last 5 years, the
linician should determine the patient’s perioperative risk
redictors (see definitions in the following text). If major
ms*
typical/Probable
Angina Pectoris
Nonanginal
Chest Pain Asymptomatic
Intermediate Low Very low
Very low Very low Very low
Intermediate Intermediate Low
Low Very low Very low
Intermediate Intermediate Low
Intermediate Low Very low
Intermediate Intermediate Low
Intermediate Intermediate Low
t probability; Low: Between 5% and 10% pre-test probability; Very Low: Less than
rs, but it can be assumed that prevalence of CAD increases with age. In a few cases,
ide the high or low range.
sting (11).
Framingham Risk Score
coronary heart disease (CHD) at any age for a non-smoker,
holesterol of 160–199 mg/dL, LDL-C 100 to 129 mg/dL,
r than or equal to 55 mg/dL in women. †Points  number
ent of Cardiovascular Risk by Use of Multiple-Risk-Factor
ase (Total CHD) includes angina pectoris, recognized and
hs. §Hard CHD includes all of the total CHD events except
, Pasternak R, Greenland P, et al. ACC/AHA scientific
sk-factor assessment equations: a statement for healthcarempto
A
re-tes
69 yeag to
isk of
total c
greate
ssessm
t Dise
D deat
dy SM
iple-rirican College of Cardiology. J Am Coll Cardiol 1999;34:
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Appropriateness Criteria for CCT/CMR October 3, 2006:1475–97isk predictors are present, coronary angiography and the
ostponement or cancellation of non-cardiac surgery
hould be considered. Once perioperative risk predictors
re assessed based on the algorithm, then the surgical risk
nd patient’s functional status should be used to establish
he need for non-invasive testing.
erioperative Risk Predictors*
Major risk predictors
Unstable coronary syndromes, decompensated heart failure
(HF), significant arrhythmias, and severe valve disease.
Intermediate risk predictors
Mild angina, prior myocardial infarction (MI), compen-
sated or prior HF, diabetes, or renal insufficiency.
Minor risk predictors
Advanced age, abnormal electrocardiogram (ECG),
rhythm other than sinus, low functional capacity, history
of cerebrovascular accident, and uncontrolled hyper-
tension.
urgical Risk Categories*
High-Risk Surgery— cardiac death or MI greater than
5%
Emergent major operations (particularly in the elderly), aortic
and peripheral vascular surgery, prolonged surgical procedures
Table B3. Women: 10-Year CHD Risk Accor
*Low-risk level is defined in the Framingham Report as the r
non-diabetic, with blood pressure less than 120/80 mmHg,
and HDL-C greater than or equal to 45 mg/dL in men and
of points estimated from ACC/AHA Scientific Statement: A
Assessment Equations, Table 4 (7). ‡Total Coronary Hear
unrecognized myocardial infarction, unstable angina, and CH
for angina pectoris. Reprinted with permission from Grun
statement: assessment of cardiovascular risk by use of mult
professionals from the American Heart Association and th
1348–59 (7).associated with large fluid shifts and/or blood loss. GIntermediate-Risk Surgery— cardiac death or MI 
1% to 5%
Carotid endarterectomy, head and neck surgery, surgery of the
chest or abdomen, orthopedic surgery, prostate surgery.
Low-Risk Surgery— cardiac death or MI less than 1%
Endoscopic procedures, superficial procedures, cataract
surgery, breast surgery.
As defined by the ACC/AHAGuideline Update for Perioperative
ardiovascular Evaluation of Non-Cardiac Surgery (13).
CG—Uninterpretable
efers to ECGs with resting ST-segment depression
greater than or equal to 0.10 mV), complete left bundle-
ranch block, pre-excitation (Wolf-Parkinson-White syn-
rome), or paced rhythm.
PPENDIX C: ACCF APPROPRIATENESS
RITERIA WORKING GROUP AND TECHNICAL PANEL
CT/CMR Writing Group
Robert C. Hendel, MD, FACC, Moderator of the
echnical Panel, Midwest Heart Specialists, Fox River
to Framingham Risk Score
coronary heart disease (CHD) at any age for a non-smoker,
holesterol of 160–199 mg/dL, LDL-C 100 to 129 mg/dL,
r than or equal to 55 mg/dL in women. †Points  number
ent of Cardiovascular Risk by Use of Multiple-Risk-Factor
ase (Total CHD) includes angina pectoris, recognized and
hs. §Hard CHD includes all of the total CHD events except
, Pasternak R, Greenland P, et al. ACC/AHA scientific
sk-factor assessment equations: a statement for healthcare
rican College of Cardiology. J Am Coll Cardiol 1999;34:ding
isk of
total c
greate
ssessm
t Dise
D deat
dy SM
iple-rirove, IL.
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able D1. ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR Appropriateness Criteria Writing Group, Technical Panel,
orking Group, and Indication Reviewers (In Alphabetical Order)
Committee Member Research Grant
Speakers Bureau/Honoraries/
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Stock
Ownership
Board of
Directors
Consultant/Advisory Board/
Steering Committee
CCT/CMR Appropriateness Criteria Writing Group
r. Robert C. Hendel ● Astellas Healthcare
● GE Healthcare
● Cornatus Genetics
● Bristol-Myers Squibb ● GE Healthcare
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r. Chirstopher Kramer ● Siemens Medical Solutions
● Novartis Healthcare
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● GE Healthcare ● GE Healthcare
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r. John Hodgson ● GE Healthcare ● GE Healthcare
r. Raymond Kim ● Siemens Medical Solutions ● Mallinckrodt
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● Novartis Healthcare
● Astellas Healthcare
● GE Healthcare ● GE Healthcare
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r. Edward Martin ● Guidant Corporation ● GE Healthcare ● Guidant Corporation
● GE Healthcare
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● GE Healthcare
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● GE Healthcare
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